|
1
|
Cowan AJ, Allen C, Barac A, Basaleem H,
Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, et
al: Global burden of multiple myeloma: A systematic analysis for
the global burden of disease study 2016. JAMA Oncol. 4:1221–1227.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alsop BR and Sharma P: Esophageal cancer.
Gastroenterol Clin North Am. 45:399–412. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lou F, Sima CS, Adusumilli PS, Bains MS,
Sarkaria IS, Rusch VW and Rizk NP: Esophageal cancer recurrence
patterns and implications for surveillance. J Thorac Oncol.
8:1558–1562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey
SM, Dong ZW, Mark SD, Qiao YL and Taylor PR: Prospective study of
risk factors for esophageal and gastric cancers in the Linxian
general population trial cohort in China. Int J Cancer.
113:456–463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arnold M, Soerjomataram I, Ferlay J and
Forman D: Global incidence of oesophageal cancer by histological
subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zou S, Yang J, Guo J, Su Y, He C, Wu J, Yu
L, Ding WQ and Zhou J: RAD18 promotes the migration and invasion of
esophageal squamous cell cancer via the JNK-MMPs pathway. Cancer
Lett. 417:65–74. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Richter AM, Pfeifer GP and Dammann RH: The
RASSF proteins in cancer; From epigenetic silencing to functional
characterization. Biochim Biophys Acta. 1796:114–128.
2009.PubMed/NCBI
|
|
8
|
Sherwood V, Recino A, Jeffries A, Ward A
and Chalmers AD: The N-terminal RASSF family: A new group of
Ras-association-domain-containing proteins, with emerging links to
cancer formation. Biochem J. 425:303–311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Underhill-Day N, Hill V and Latif F:
N-terminal RASSF family: RASSF7-RASSF10. Epigenetics. 6:284–292.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Helmbold P, Richter AM, Walesch S,
Skorokhod A, Marsch WCh, Enk A and Dammann RH: RASSF10 promoter
hypermethylation is frequent in malignant melanoma of the skin but
uncommon in nevus cell nevi. J Invest Dermatol. 132(3 Pt 1):
687–694. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hesson LB, Dunwell TL, Cooper WN,
Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD,
Maher ER and Latif F: The novel RASSF6 and RASSF10 candidate tumour
suppressor genes are frequently epigenetically inactivated in
childhood leukaemias. Mol Cancer. 8:422009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hill VK, Underhill-Day N, Krex D, Robel K,
Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher
ER and Latif F: Epigenetic inactivation of the RASSF10 candidate
tumor suppressor gene is a frequent and an early event in
gliomagenesis. Oncogene. 30:978–989. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schagdarsurengin U, Richter AM, Wöhler C
and Dammann RH: Frequent epigenetic inactivation of RASSF10 in
thyroid cancer. Epigenetics. 4:571–576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu X, Yu AX, Qi BW, Fu T, Wu G, Zhou M,
Luo J and Xu JH: The expression and significance of IDH1 and p53 in
osteosarcoma. J Exp Clin Cancer Res. 29:432010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kimura M: A simple method for estimating
evolutionary rates of base substitutions through comparative
studies of nucleotide sequences. J Mol Evol. 16:111–120. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Q, Yao YT, Xu H, Chen YB, Gu M, Cai
ZK and Wang Z: SPOCK1 promotes tumor growth and metastasis in human
prostate cancer. Drug Des Devel Ther. 10:2311–2321. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheung CT, Singh R, Kalra RS, Kaul SC and
Wadhwa R: Collaborator of ARF (CARF) regulates proliferative fate
of human cells by dose-dependent regulation of DNA damage
signaling. J Biol Chem. 289:18258–18269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Zhi X, Shi S, Tao R, Chen P, Sun
S, Bian L, Xu Z and Ma L: SPOCK1 is up-regulated and promotes tumor
growth via the PI3K/AKT signaling pathway in colorectal cancer.
Biochem Biophys Res Commun. 482:870–876. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao Y, Yi J, Zhang K, Bai F, Feng B, Wang
R, Chu X, Chen L and Song H: Downregulation of MiR-31 stimulates
expression of LATS2 via the hippo pathway and promotes
epithelial-mesenchymal transition in esophageal squamous cell
carcinoma. J Exp Clin Cancer Res. 36:1612017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang F, Feng Y, Li P, Wang K, Feng L, Liu
YF, Huang H, Guo YB, Mao QS and Xue WJ: RASSF10 is an
epigenetically inactivated tumor suppressor and independent
prognostic factor in hepatocellular carcinoma. Oncotarget.
7:4279–4297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu R, Liu Y, Zhou H, Li L, Li Y, Ding F,
Cao X and Liu Z: Deubiquitinating enzyme PSMD14 promotes tumor
metastasis through stabilizing SNAIL in human esophageal squamous
cell carcinoma. Cancer Lett. 418:125–134. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei Z, Chen X, Chen J, Wang W, Xu X and
Cai Q: RASSF10 is epigenetically silenced and functions as a tumor
suppressor in gastric cancer. Biochem Biophys Res Commun.
432:632–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tarapore RS, Yang Y and Katz JP: Restoring
KLF5 in esophageal squamous cell cancer cells activates the JNK
pathway leading to apoptosis and reduced cell survival. Neoplasia.
15:472–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang F, Li P, Feng Y, Hu YL, Liu YF, Guo
YB, Jiang XL, Mao QS and Xue WJ: Low expression of RASSF10 is
associated with poor survival in patients with colorectal cancer.
Hum Pathol. 62:108–114. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu D, Ma J, Zhan Q, Li Y, Qin J and Guo M:
Epigenetic silencing of RASSF10 promotes tumor growth in esophageal
squamous cell carcinoma. Discov Med. 17:169–178. 2014.PubMed/NCBI
|
|
28
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fan C, Wang W, Jin J, Yu Z and Xin X:
RASSF10 is epigenetically inactivated and suppresses cell
proliferation and induces cell apoptosis by activating the p53
signalling pathway in papillary thyroid carcinoma cancer. Cell
Physiol Biochem. 41:1229–1239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Figiel S, Vasseur C, Bruyere F, Rozet F,
Maheo K and Fromont G: Clinical significance of
epithelial-mesenchymal transition markers in prostate cancer. Hum
Pathol. 61:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fukuda K, Takeuchi S, Arai S, Katayama R,
Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki
T, et al: Epithelial-to-mesenchymal transition is a mechanism of
ALK inhibitor resistance in lung cancer independent of ALK mutation
status. Cancer Res. 79:1658–1670. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Das V, Bhattacharya S, Chikkaputtaiah C,
Hazra S and Pal M: The basics of epithelial-mesenchymal transition
(EMT): A study from a structure, dynamics, and functional
perspective. J Cell Physiol. Feb 5–2019.(Epub ahead of print).
View Article : Google Scholar
|
|
33
|
Zhang C and Wang Y: Metformin attenuates
cells stemness and epithelial-mesenchymal transition in colorectal
cancer cells by inhibiting the Wnt3a/β-catenin pathway. Mol Med
Rep. 19:1203–1209. 2019.PubMed/NCBI
|
|
34
|
He J, Zhou M, Chen X, Yue D, Yang L, Qin
G, Zhang Z, Gao Q, Wang D, Zhang C, et al: Inhibition of SALL4
reduces tumorigenicity involving epithelial-mesenchymal transition
via Wnt/β-catenin pathway in esophageal squamous cell carcinoma. J
Exp Clin Cancer Res. 35:982016. View Article : Google Scholar : PubMed/NCBI
|
